

- 1) Asahina, Hajime, Kentaro Tanaka, Satoshi Morita, Makoto Maemondo, Masahiro Seike, Isamu Okamoto, Satoshi Oizumi, et al. 2021. "A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801)." *Clinical Lung Cancer* 22 (2): 147–151. doi:10.1016/j.clcc.2020.09.023.
- 2) Chiba, Shinji, Masachika Akiyama, Kazuhiro Yakuwa, Hideomi Sato, Kunio Hirano, Yu Utsumi, Hiromi Nagashima, Tamotsu Sugai, and Makoto Maemondo. 2021. "Combination Treatment with Bevacizumab plus Erlotinib for Meningeal Carcinomatosis of Afatinib-Resistant EGFR Mutated Lung Cancer without T790M Mutation: A Case Report." *Annals of Palliative Medicine* 0 (0): 0–0. doi:10.21037/apm-21-1885.
- 3) Chiba, Shinji, and Makoto Maemondo. 2021. "[ I . Development and Advances in Molecular Targeted Therapy for Lung Cancer]." *Gan to Kagaku Ryoho. Cancer & Chemotherapy* 48 (8): 1014–1022.
- 4) Ito, Takashi, Hiromi Nagashima, Masachika Akiyama, Yu Utsumi, Hideomi Sato, Shinji Chiba, Mayu Sugai, et al. 2021. "Treatment with Immune Checkpoint Inhibitors after EGFR - TKIs in EGFR - mutated Lung Cancer." *Thoracic Cancer*. doi:10.1111/1759-7714.14267.
- 5) Japan, North Japan Lung Cancer Study Group, Sendai, Kana Watanabe, Yukihiro Toi, Atsushi Nakamura, Ryosuke Chiba, Masachika Akiyama, Jun Sakakibara-Konishi, et al. 2021. "Randomized Phase II Trial of Uracil/Tegafur and Cisplatin versus Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy for Locally Advanced Unresectable Stage III Non-Squamous Non-Small Cell Lung Cancer: NJLCG1001." *Translational Lung Cancer Research* 10 (2): 712–722. doi:10.21037/tlcr-20-721.
- 6) Kawashima, Yosuke, Tatsuro Fukuhara, Haruhiro Saito, Naoki Furuya, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, et al. 2022. "Bevacizumab plus Erlotinib versus Erlotinib Alone in Japanese Patients with Advanced, Metastatic, EGFR-Mutant Non-Small-Cell Lung Cancer (NEJ026): Overall Survival Analysis of an Open-Label, Randomised, Multicentre, Phase 3 Trial." *The Lancet Respiratory Medicine* 10 (1): 72–82. doi:10.1016/s2213-2600(21)00166-1.
- 7) Murata, Okinori, Katsuya Suzuki, Tsutomu Takeuchi, and Makoto Maemondo. 2021. "The Risk Factors of Exacerbation in Interstitial Pneumonia

- With Autoimmune Features: A Single-Center Observational Cohort Study.” *Rheumatology and Therapy* 8 (4): 1693–1710. doi:10.1007/s40744-021-00371-3.
- 8) Saikawa, Hirotaka, Hiromi Nagashima, Katsuya Cho, Ryosuke Chiba, Koichiro Sera, Wataru Shigeeda, Makoto Tomoyasu, et al. 2021. “Relationship between Trace Element in Tumor and Prognosis in Lung Cancer Patients.” *Medicina (Kaunas, Lithuania)* 57 (3): 209. doi:10.3390/medicina57030209.
- 9) Saka, Hideo, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, et al. 2021. “Five-Year Follow-up Results from Phase II Studies of Nivolumab in Japanese Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: Pooled Analysis of the ONO-4538-05 and ONO-4538-06 Studies.” *Japanese Journal of Clinical Oncology* 51 (1): 106–113. doi:10.1093/jjco/hyaa157.
- 10) Sato, Hideomi, Hiromi Nagashima, Masachika Akiyama, Takashi Ito, Tatsuya Hashimoto, Hirotaka Saikawa, Yu Utsumi, and Makoto Maemondo. 2021. “Analysis of Bevacizumab Treatments and Metastatic Sites of Lung Cancer.” *Cancer Treatment and Research Communications* 26: 100290. doi:10.1016/j.ctarc.2020.100290.
- 11) Tanaka, Hisashi, Yukihiro Hasegawa, Yuka Fujita, Atsushi Nakamura, Eiki Kikuchi, Yasutaka Kawai, Toshiyuki Harada, et al. 2021. “Randomized Phase 2 Study Comparing Irinotecan versus Amrubicin as Maintenance Therapy after First-line Induction Therapy for Extensive Disease Small Cell Lung Cancer (HOT1401/NJLCG1401).” *Thoracic Cancer* 12 (14): 2113–2121. doi:10.1111/1759-7714.14048.
- 12) Tsubata, Yukari, Kana Watanabe, Ryota Saito, Atsushi Nakamura, Hiroshige Yoshioka, Mami Morita, Ryoichi Honda, et al. 2021. “Osimertinib in Poor Performance Status Patients with T790M-Positive Advanced Non-Small-Cell Lung Cancer after Progression of First- and Second-Generation EGFR-TKI Treatments (NEJ032B).” *International Journal of Clinical Oncology*, 1–9. doi:10.1007/s10147-021-02043-2.
- 13) Yanagawa, Naoki, Noriyuki Yamada, Ryo Sugimoto, Mitsumasa Osakabe, Noriyuki Uesugi, Satoshi Shiono, Makoto Endoh, et al. 2021. “The Frequency of DNA Mismatch Repair Deficiency Is Very Low in Surgically Resected Lung Carcinoma.” *Frontiers in Oncology* 11: 752005. doi:10.3389/fonc.2021.752005.